Alcon price target raised to $100 from $90 at Argus

Argus raised the firm’s price target on Alcon to $100 from $90 and keeps a Buy rating on the shares after its Q4 earnings beat. The firm is positive on the company’s market position and product pipeline, noting that its sales growth has outpaced increases in marketing and selling costs, resulting in higher margins, the analyst tells investors in a research note. Argus further cites Alcon continuing to release new products and services, such as its recently unveiled MARLO App, and a treatment for dry eye disease, currently in trials, which it plans to file with the FDA in mid-2024.